Article

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS

2022-11-02

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> ALK activating mutations are identified in approximately 10% of newly diagnosed neuroblastomas and ALK amplifications in a further 1-2% of cases. Lorlatinib, a third generation ALK inhibitor, will soon be given alongside induction chemotherapy for children with ALK-aberrant neuroblastoma. However, resistance to single agent treatment has been reported and therapies that imp...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d15912d7-29b3-5aa8-9282-2859ad36ea16
DOI: 10.1101/2022.10.30.512477

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELSDOI 10.1101/2022.10.30.512477Read

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsSemantic proximity Read

Targeted Therapy for Neuroblastoma: ALK InhibitorsSemantic proximity Read

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.Semantic proximity Read

Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified NeuroblastomaSemantic proximity Read

ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.Semantic proximity Read

Targeting anaplastic lymphoma kinase in neuroblastomaSemantic proximity Read

ALK in Neuroblastoma: Biological and Therapeutic ImplicationsSemantic proximity Read

ALK/ATR combination therapy is effective in neuroblastoma mouse tumors driven by MYCNSemantic proximity Read

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastomaSemantic proximity Read

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft modelsSemantic proximity Read

SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in NeuroblastomaSemantic proximity Read

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Semantic proximity Read